MULPLETA
Peaklusutrombopag
NDAORALTABLETPriority Review
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
5/8 — Partial
Priority Review
MULPLETA (lusutrombopag) is bioavailable, small molecule tpo receptor agonist that interacts with the transmembrane domain of human tpo receptors expressed on megakaryocytes to induce the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells and megakaryocyte maturation. First approved in 2018.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MULPLETA (lusutrombopag) is an oral, bioavailable small molecule TPO receptor agonist approved in 2018 that stimulates megakaryocyte proliferation and maturation to increase platelet counts. It works by binding to transmembrane TPO receptors on megakaryocytes, triggering differentiation of hematopoietic progenitor cells. The drug is indicated for patients requiring platelet count elevation prior to medical procedures.
$0.278MPart D
Peak5.2 years to LOEProduct is at peak lifecycle with minimal spending ($278K in 2023, 30 claims) suggesting a narrow patient population and smaller commercial team footprint.
Mechanism of Action
bioavailable, small molecule TPO receptor agonist that interacts with the transmembrane domain of human TPO receptors expressed on megakaryocytes to induce the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells and megakaryocyte maturation.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag
Started Jun 2024
40 enrolled
Aplastic Anemia
Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
Started Jun 2015
215 enrolled
Chronic Liver DiseaseThrombocytopenia
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
Started Apr 2010
19 enrolled
Immune Thrombocytopenia
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
Started Mar 2010
20 enrolled
Immune Thrombocytopenia (ITP)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.